The One Big Beautiful Bill: What It Means for the Future of US Healthcare
Explore how OBBBA is reshaping US healthcare as it relates to coverage, funding, and pharma strategy in this breakdown with PwC health leaders.
Featured - 4 items
- 100 results
- Reset filters
Loading...
Turning oncology data into action: A cloud-first leap toward smarter care and faster research with AI
PwC and Google Cloud helped a healthcare provider use AI to unify data, improving cancer care, clinical trial matching and saving $50M+ annually.
Medical cost trend: Behind the numbers 2026
Help guide providers, payers, pharma companies and employers as they determine medical cost trends and the factors driving or dampening spending in 2026.
Strategic Dealmaking in Health: Navigating Midyear Trends in 2025
PwC specialists unpack how regulatory changes, pricing pressures, and global innovation are influencing pharma and health services M&A—and what companies should do now to reassess pricing strategies, stabilize supply chains, and navigate policy risk.
Future-proof your pharma supply chain: three moves to make now
Rewire your pharma supply chain strategy with three decisive actions you can take now—while navigating shifting policy landscapes and geopolitical changes.
The One Big Beautiful Bill Act (OBBBA): A trillion-dollar turn in US health policy
How the One Big Beautiful Bill reshapes US healthcare and what providers, payors, PBMs and pharma should do to respond to policy, funding and coverage shifts.
Health services: US Deals 2025 midyear outlook
Health services M&A has weathered a complicated macroeconomic and political environment but, strong subsector growth demonstrates sector durability.
Pharmaceutical and life sciences: US Deals 2025 midyear outlook
Companies are responding with targeted mitigation strategies, while maintaining flexibility as tariff policies continue to evolve.
Health industries quarterly insights: Q2 2025
The health industries quarterly offers insights on accounting and reporting hot topics impacting the industry.
Taking a closer look at the Most Favored Nation Pricing Executive Order
PwC specialists break down MFN drug pricing and what companies should do now to reassess pricing, supply chains, and policy risks.
US GAAP – Issues and solutions for pharmaceutical and life sciences
This publication highlights industry-specific factors to be considered and provides guidance on the most pertinent accounting solutions for the pharmaceutical, life sciences and medical device industry.
Navigating the FDA disruption: 4 key actions for pharma
Explore how pharma and biotech leaders can navigate FDA disruption with smarter submissions, regulatory agility, and global risk mitigation strategies.
Loading...
Follow us
